Search

Introduction: The Mobile Health (mHealth) Intervention for Dementia Prevention through lifestyle Optimisation (MIND-PRO) study addresses the increasing prevalence of dementia among populations with lower socio-economic status (SES) and/or a migration background. The study aims to evaluate the effectiveness and implementation of an mHealth intervention designed for self-managing lifestyle modifications with remote coaching to reduce dementia risk factors., Methods and Analysis: This prospective randomised open-label blinded end point (PROBE) trial follows a type 2 hybrid effectiveness-implementation design with a 12-month intervention period. It aims to recruit 692 participants in Dutch primary care. Entry criteria include age 50-75 years, low SES and/or migration background, one or more dementia risk factors (hypertension, dyslipidaemia, diabetes mellitus, physical inactivity, smoking, depression and overweight) or manifest cardiovascular disease and possession of a smartphone. Participants are randomised to a coach-supported, interactive app facilitating self-management of dementia risk factors or to a control app with static health information. The primary effectiveness outcome is a composite score of systolic blood pressure, non-high-density lipoprotein cholesterol and body mass index. Implementation outcomes include coverage, adoption, acceptability, appropriateness, feasibility, fidelity, costs and sustainability of the intervention. Secondary outcomes include the Cardiovascular Risk Factors, Ageing and Dementia risk score and its individual risk factors, and disability, physical activity, depressive symptoms, cognitive functioning and daily distance moved., Ethics and Dissemination: The MIND-PRO trial is funded by the Netherlands Organisation for Health Research and Development (ZonMw, grant number 10510032120004) and approved by the Ethics Committee of Amsterdam UMC (reference: METC 2023.0770). Results are expected in 2026 and will be submitted for publication in a peer-reviewed journal, and presented at scientific conferences., Trial Registration Number: ISRCTN92928122., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY. Published by BMJ Group.)

Background and Purpose: Irwin tests are key preclinical study elements for characterising drug-induced neurological side effects. This multicentre study aimed to assess the robustness of Irwin tests across multinational sites during three stages of protocol harmonisation. The projects were part of the Enhanced Quality in Preclinical Data framework, aiming to increase success rates in transition from preclinical testing to clinical application., Experimental Approach: Female and male NMRI mice were assigned to one of three groups (vehicle, MK-801 0.1 and 0.3 mg kg -1 ). Irwin scores were assessed at baseline and multiple times following intraperitoneal injection of MK-801 using local protocols (Stage 1), shared protocols with harmonised environmental design (Stage 2) and fully harmonised Irwin scoring protocols (Stage 3)., Key Results: The analysis based on the four functional domains (motor, autonomic, sedation and excitation) revealed substantial data variability in Stages 1 and 2. Although there was still marked overall heterogeneity between sites in Stage 3 after complete harmonisation of the Irwin scoring scheme, heterogeneity was only moderate within functional domains. When comparing treatment groups versus vehicle, we found large effect sizes in the motor domain and subtle to moderate effects in the excitation-related and autonomic domains., Conclusion and Implications: The pronounced interlaboratory variability in Irwin datasets for the CNS-active compound MK-801 needs to be carefully considered when making decisions during drug development. While environmental and general study design had a minor impact, the study suggests that harmonisation of parameters and their scoring can limit variability and increase robustness., (© 2024 The Author(s). British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.)

Given the pervasive role of smartphones in modern life, research into their impact on well-being has flourished. This study addresses existing methodological shortcomings using smartphone log data and experience sampling methods (ESM) to explore the bidirectional within-person relationship between smartphone usage and momentary well-being variables (i.e., affect valence, loneliness, positive affect, and negative affect). We further examine different categories of smartphone usage, namely, communication, social media, and other apps. We analyze three samples ( N ₁ = 225, N ₂ = 17, N ₃ = 13; with T ₁ = 7,874, T ₂ = 2,566, T ₃ = 1,533 ESM reports) with multilevel models to test our preregistered hypotheses. Data for Sample I were collected in Spain in 2022 (82% female; M age = 23.1). Samples II and III (80% female; M age = 21.6) were collected in the Netherlands between 2021 and 2022. Our results suggest that smartphone usage within an hour before ESM assessment, especially using social media apps, is associated with reduced affect valence and increased loneliness on a within-person level. Loneliness was associated with more smartphone usage than usual, particularly the use of social media apps, within the hour following ESM assessments. However, overall, our findings indicate weak bidirectional associations between smartphone usage and indicators of momentary well-being (range standardized β = .00-.08). On the between-person level, those individuals generally high in loneliness were more affected in their momentary loneliness by prior social media use, suggesting a heightened social media sensitivity. The interplay between social media use and momentary loneliness should be studied in more detail, including contextual factors and experimental designs. (PsycInfo Database Record (c) 2025 APA, all rights reserved).

Current nosology claims to separate mental disorders into distinct categories that do not overlap with each other. This nosological separation is not based on underlying pathophysiology but on convention-based clustering of qualitative symptoms of disorders which are typically measured subjectively. Yet, clinical heterogeneity and diagnostic overlap in disease symptoms and dimensions within and across different diagnostic categories of mental disorders is huge. While diagnostic categories provide the basis for general clinical management, they do not describe the underlying neurobiology that gives rise to individual symptomatic presentations. The ability to incorporate neurobiology into the diagnostic framework and to stratify patients accordingly will be a critical step forward for the development of new treatments for mental disorders. Furthermore, it will also allow physicians to provide patients with a better understanding of their illness's complexities and management. To realize this ambition, a paradigm shift is needed to build an understanding of how neuropsychiatric conditions can be defined more precisely using quantitative (multimodal) biological processes and markers and thus to significantly improve treatment success. The ECNP New Frontiers Meeting 2024 set out to develop a consensus roadmap for building a new diagnostic framework for mental disorders by discussing its rationale, outlook, and consequences with all stakeholders involved. This framework would instantiate a set of principles and procedures by which research could continuously improve precision diagnostics while moving away from traditional nosology. In this meeting report, the speakers' summaries from their presentations are combined to address three key elements for generating such a roadmap, namely, the application of innovative technologies, understanding the biology of mental illness, and translating biological understanding into new approaches. In general, the meeting indicated a crucial need for a biology-informed framework to establish more precise diagnosis and treatment for mental disorders to facilitate bringing the right treatment to the right patient at the right time., Competing Interests: Declaration of competing interest MJHK, DHM, MH, and BC declare no conflict of interest. SH is member of the scientific advisory boards for Johnson and Johnson (formerly Janssen) and F-Prime Capital, and he is member of the Boards of Directors for Voyager Therapeutics, Cyclerion Therapeutics, and Vesalius Therapeutics. LMW discloses the following patents in which she contributed, namely, US Patent App. 16/921,388, 16/368,774, 10,702,232 B2, 15/997,631, 10,285,658, 15/830,338, 10,034,645. LJdP declared consultancy and paid presentations for Boeringer-Ingelheim, paid presentation for Viatris – all outside the current work. LJdP is also the Co-chair of the ECNP Immuno-NeuroPsychiatry Network. CML is SAB for Myriad Neuroscience. Speaker & Consultancy fees from UCB and SYNLAB. AE receives salary and equity from Alto Neuroscience, and equity from Akili Interactive. PAL has received honoraria for talks presented at educational meetings organised by Boehringer-Ingelheim outside of the presented work. QJMH has obtained fees and options for consultancies for Aya Technologies and Alto Neuroscience. HM is a full-time employee of Boehringer Ingelheim Pharma GmbH., (Copyright © 2024. Published by Elsevier B.V.)